Board of Directors.
Simos Simeonidis, Ph.D.
Simos Simeonidis, Ph.D. has served on our board of directors since June 2019. Dr. Simeonidis has served as Portfolio Manager, Co-Chief Executive Officer & Co-Chief Investment Officer of Ally Bridge Group since July 2022. Previously, he served as a partner at Sarissa Capital from June 2017 to November 2021. Prior to joining Sarissa Capital, he was a managing director and senior biotechnology analyst at the Royal Bank of Canada in New York from July 2014 to June 2017. Dr. Simeonidis spent more than a decade covering the biotechnology sector as an analyst at a number of investment banks, including Cowen and Company, First Albany Capital and Morgan Stanley. In addition to his investment management and financial expertise, Dr. Simeonidis combines both biopharmaceutical industry and biomedical research expertise, having worked at Novartis International AG in business development and strategic planning, and prior to his corporate career, having served as a faculty member at Harvard Medical School. Dr. Simeonidis received his B.S. in biology from Loyola University Chicago, and his M.A., MPhil and Ph.D. degrees in cellular, molecular and biophysical sciences from Columbia University’s College of Physicians and Surgeons. He completed his postdoctoral fellowship at the laboratory of Professor Tucker Collins at Harvard Medical School and the Brigham and Women’s Hospital, where he worked on the transcriptional regulation of gene expression. Dr. Simeonidis also holds an MBA in healthcare management of the Wharton School of the University of Pennsylvania.